[Bisphosphonates first-line pharmacological treatment].
Karolinska University Hospital - Department of Endocrinology Stockholm, Sweden Karolinska University Hospital - Department of Endocrinology Stockholm, Sweden.
Märit
M
Wallander
Uppsala universitet - institutionen för medicinska vetenskaper Uppsala, Sweden - , Sweden.
Östen
Ö
Ljunggren
Osteoporosmottagningen - Geriatriska kliniken, Sahlgrenska universitetssjukhset, Mölndal Mölndal, Sweden Geriatric Medicine - Institute of Medicine Mölndal, Sweden.
Mattias
M
Lorentzon
D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002118:Calcium / Q000008:administration & dosage / Q000627:therapeutic use; D000069448:Denosumab / Q000008:administration & dosage / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D010024:Osteoporosis / Q000188:drug therapy*; D019379:Teriparatide / Q000008:administration & dosage / Q000627:therapeutic use; D014807:Vitamin D / Q000008:administration & dosage / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D019379:Teriparatide; D014807:Vitamin D; D000069448:Denosumab; D002118:Calcium